Teva is in a range... Follow the price.TEVA is oversold on the daily RSI and has been consolidating there for a few days. I believe that a close on the daily and weekly above the $16.60 area should break us higher. Money is flowing into the April $18 calls. That is where my money is at this moment. Watch the consolidation zone per my chart and keep watch on a weekly or daily close below $16. 50's area. It could try and complete a H&S. Longby OptionFishing2
Teva Is In A Range... Follow The PriceTEVA is oversold on the daily RSI. However, TEVA could complete a H&S pattern if it closes the weekly and daily below $16.60 (below the trend line). If it breaks higher, you should see a close both on the daily and weekly above the $16.60 area. If it spikes based on market sentiment you could see $18 by April. Longby OptionFishing1
TEVA is a great downtrend and Gives a selling opportunity.Sell Teva now. We are in a downtrend and the price gives us a good opportunity to sell Shortby IhabMaxUpdated 2
OPENING: TEVA MARCH 15TH 15/19/19/23 IRON FLY... for a 2.00/contract credit. Metrics: Max Profit: $200 Max Loss: $200 Break Evens: 17.00/21.00 Theta: 2.05 Delta: -3.92 Notes: A classic risk one to make one iron fly. Will look to take profit at 25% max.by NaughtyPinesUpdated 3
THE WEEK AHEAD: TEVA, BIDU, RIG, XOPBIDU (44/42), RIG (33/56), and TEVA (49/53) announce earnings this week, with TEVA looking for a March to April volatility contraction of about 15%, BIDU, approximately 7.7%, and RIG, 6.9%. Instead of looking to play these pre-announcement for a volatility contraction (the contraction percentages aren't that compelling), I'll look to potentially short put/acquire/cover instead,* particularly since all of these underlyings have been hammered of late and are at the low end of their 52-week ranges. Pictured here is a Plain Jane, TEVA 20-ish delta 16 short put in the April expiry; it's paying .51 with a break even of 15.49. The more aggressive 30 would be at the 17 strike and is currently paying .79 with a 16.21 break even. On margin, the 16 short ties up about 320 to put on, the 17, 340, with respective returns on capital of 16% and 23% at max. The break evens represent a 15% discount over current price for the 16 short put; an 11% discount for the 17. The BIDU April 18th 155 (25 delta) is paying a 4.55 credit with a break even of 150.45, a potential 14.7% return on capital at max and a 11.4% discount over current price if assigned. As with TEVA, there is little point in holding shares if you don't have to, since it does not pay a divvy. If you end up in-the-money, roll as is and proceed to sell calls against to reduce cost basis. If you're not into tying up 31.00 in buying power on Baidu, there is RIG. Unfortunately, due to its size, you're going to have to go closer to the money to make it worthwhile in dollar and cents terms: the April 15th 8 short put (40 delta) is paying .57 with a break even of 7.43 -- a 35.6% potential return on capital at max and a 10.3% discount over current price if assigned. On the exchange-traded fund front, not much is hopping from a premium selling standpoint with VIX dropping into the 15's from its 2018 year-end highs of 36+, so I'll be looking to hand sit and keep powder dry for a higher volatility environment to get into nondirectional setups in broad market instruments. That being said, I will continue to sell premium in XOP, where the 30-day implied is over twice that of the broader market (34.1% versus SPY 15%). * -- The natural alternative should you not be interested in acquiring shares would be to roll the short put out in time "as is" if it hasn't worked out and then proceed to cover with a short call. The last two dividends were a paltry .07, so I could see not wanting to tie up buying power to be in the shares unless you absolutely have to. by NaughtyPines6
Long $TEVA Pharmaceutical StockTEVA develops, manufactures and sells generic medicine in a range of forms including tablets, capsules, injectables, inhalants, liquids, ointments and creams. They also create specific speciality medicines that assist the Central Nervous System and Respiratory medicines focused on asthma and chronic obstructive pulmonary disease. One of their primary drugs is Copaxone.. used to treat multiple sclerosis however we are seeing more and more generic competition come into the marketplace. Teva Investor FAQ: ir.tevapharm.com See past analysis for more insight on what happened when it was publically disclosed that Warren Buffet increased his stake to owning 4.25% of the entire companies stock. Pros: Cheap/Mid Range Stock Price Wealthy Investment Firms Are Positioned Longstanding Global Brand Cons Pharma Sector Competition No more dividends paid to holders as of this time At risk of further bearish movement if the stock market falls due to overvaluation on major indexes Trading can contain substantial risk and is not suited for every investor. An investor could potentially lose all or more than their initial investment. "Risk capital" - is money that can be lost without jeopardizing ones financial security or life style. Only "risk capital" should be used for trading and only those with sufficient risk capital should consider trading. I am not a licensed financial advisor nor do I give out financial advice. You assumes full risk and responsibility for their trading activity. Past performance is not indicative of future results. Individual results will vary due to a variety of market and timing conditions.Longby ZacharyHogan5
tevalong teva is what i think, because it broke the downtrend and a big support.Longby adjankUpdated 2
TEVA on the 4-HrI am long TEVA and feel we are a bit over-extended on price action North and hoping for a pullback to $17.80 or lower to get more (If not, oh well). I have a $21.00 price target (3-weeks) timeframe. Let's see if there is some profit taking to bring the price action down to the level mentioned. This analysis speaks for itself -- the chart display's a V-Bottom on the 4-Hr and the stock has taken a beating. Warren Buffet took a position in this company just before it fell, so I will follow the money! Good Luck, Biff Longby biffbifford3
$TEVAAscending traingle but no volume, very suspicious. Would usually long this set up but will wait for confirmation and volume income. by DarioTrades1
$TEVABear flag seems about to break downwards. I would aim that order block (green box) for a conservative target. Target 2 is possible but may take a little longer. Shortby DarioTrades0
Low volume PullbackI see a low volume pullback here, it is possible price wont be able to close above the support/Resistance level.Shortby joseramonperezq2Updated 2
Teva to 30$ TEVA was saved by the 50 weeks MA line. The stock is now back above a weekly uptrend line. If it will hold above it and close above it... chances are that we will see TEVA advancing towards 30$ Longby themarketzone0
Teva possible break-outToday is possible that Teva may break the upside line of the descending channel as drawn in the picture. In this case, first TP1 is fixed at 25.14 dollars, TP2 at 27,74.by TRADOMICS_3
A Technical Analysis Look at TEVA Stock Any TEVA stock price falling on or below the hypothesized mean of $22.00, will signal the initiation of a buy order. On the other hand, any price rising above the hypothesized mean of $22.00 or within the range of $22.00 to $23.26 and above, will signal the initiation of a sell order. As of writing this Technical Indicator article, (November 5, 2018) the price of TEVA hit a low of $21.98, which is well within our target range of initiating a buy order. Therefore, if we had bought the stock at our hypothesized buy range of $22.00 or below, we would have made a nice profit of $0.85 (cents) per share because the stock closed at a $22.85 per share, a change of $0.26 (cents) per share, which is a 1.15% change for the day (November 5, 2018). Not only that, an early morning trade right after the market opened at 9:45 am would have given us a nice gain of $1.26 per share if we had followed our Mstardom Finance trading strategy of closing our long position or shorting the stock when it got to our range’s upper limit garget of $23.26. As soon as the price hit our $23.26 target, we would’ve had to exit the trade because in trading, greed causes traders to lose money, so as wise traders, we would’ve exited the trade several minutes before the stock got to its high point of $23.34. The Mstardom Finance community doesn’t care about a few extra pennies when we already got a sizable gain in our basket. The good thing is that this Mstardom Finance Trading Strategy is still relevant at the present time and in the not-so-distant future, once the hypothesized mean and the character of the TEVA stock stays the same. We are able to deduce such optimism because the stock has a very low volatility characteristic, based on our analytical assessment lend to us by our proprietary strategy. All we at Mstardom Finance cares about is helping the retail trader make money. So, when you hop over to Mstardom Finance, you will see articles, posts, and trading tools that provide the little retail trader with resources and information that will help him or her compete with the institutional or professional trader. This is what our upcoming trading book will be about, preventing the retail trader from being victims of the financial markets. Please click here to read the rest of the article, which includes a look at TEVA Fundamentals and how it has affected the movement of the stock Disclosure: (R) Mstardom Finance, Mstardom Finance does not provide investment advise.by mstardom1
TEVA Testing Support?Should see swing back to resistance. What are your ideas on TEVA? Longby RickOldboyUpdated 111
Teva finishing accumulation stage.Price under but close to Volume profile (POI). I think it is good time to open short position. Shortby vigasin2
TEVA- I have a bad feeling about this oneIt already had a horrible reaction to Earnings. Sure looks like this is falling out of favor.Shortby GUMBY9662C2
WARREN BUFFETT INCREASES STAKE IN TEVA TO 4.3%NEWS - 2 DAYS AGO Billionaire investor Warren Buffett increased his stake in Teva Pharmaceutical Industries to 4.3% during the second quarter of 2018, according to the quarterly financial statement from his investments firm Berkshire Hathaway. ... Altogether its stake is worth $957 million, according to Teva's closing price on Tuesday. TEVA HAS A STRONG PIPELINE OF NEW DRUGS COMING TO MARKETLongby UnknownUnicorn3159981Updated 115